Target Price | $16.85 |
Price | $8.13 |
Potential |
107.29%
register free of charge
|
Number of Estimates | 17 |
17 Analysts have issued a price target Myriad Genetics, Inc. 2026 .
The average Myriad Genetics, Inc. target price is $16.85.
This is
107.29%
register free of charge
$29.00
256.70%
register free of charge
$8.00
1.60%
register free of charge
|
|
A rating was issued by 17 analysts: 8 Analysts recommend Myriad Genetics, Inc. to buy, 5 to hold and 4 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Myriad Genetics, Inc. stock has an average upside potential 2026 of
107.29%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 837.60 | 846.26 |
11.21% | 1.03% | |
EBITDA Margin | -3.10% | 3.19% |
67.25% | 202.77% | |
Net Margin | -15.37% | -6.93% |
60.13% | 54.91% |
17 Analysts have issued a sales forecast Myriad Genetics, Inc. 2025 . The average Myriad Genetics, Inc. sales estimate is
This results in the following potential growth metrics:
13 Analysts have issued an Myriad Genetics, Inc. EBITDA forecast 2025. The average Myriad Genetics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Myriad Genetics, Inc. Analysts have issued a net profit forecast 2025. The average Myriad Genetics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.41 | -0.64 |
55.66% | 54.61% | |
P/E | negative | |
EV/Sales | 0.91 |
11 Analysts have issued a Myriad Genetics, Inc. forecast for earnings per share. The average Myriad Genetics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Myriad Genetics, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Scotiabank |
Locked
➜
Locked
|
Locked | Apr 01 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Mar 04 2025 |
B of A Securities |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
Raymond James |
Locked
➜
Locked
|
Locked | Feb 25 2025 |
UBS |
Locked
➜
Locked
|
Locked | Feb 25 2025 |
Craig-Hallum |
Locked
➜
Locked
|
Locked | Feb 12 2025 |
Analyst Rating | Date |
---|---|
Locked
Scotiabank:
Locked
➜
Locked
|
Apr 01 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Mar 12 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Mar 04 2025 |
Locked
B of A Securities:
Locked
➜
Locked
|
Mar 03 2025 |
Locked
Raymond James:
Locked
➜
Locked
|
Feb 25 2025 |
Locked
UBS:
Locked
➜
Locked
|
Feb 25 2025 |
Locked
Craig-Hallum:
Locked
➜
Locked
|
Feb 12 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.